Impact of extensively drug-resistant tuberculosis on treatment outcome of multidrug-resistant tuberculosis patients with standardized regimen: Report from Iran

Microbial Drug Resistance

Volumn 16, Issue 1, 2010, Pages 81-86

  Tabarsi, Payam ^a   Chitsaz, Ehsan ^a   Baghaei, Parvaneh ^a   Shamaei, Masoud ^a   Farnia, Parisa ^a   Marjani, Majid ^a   Kazempour, Mehdi ^a   Amiri, Majid ^a   Mansouri, Davood ^a   Masjedi, Mohammad R ^a   Velayati, Ali A ^a   Caminero, Jose A ^b,c  

^a SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b HOSPITAL UNIVERSITARIO DE GRAN CANARIA DR NEGRÍN   (Spain)

^c INTERNATIONAL UNION AGAINST TUBERCULOSIS AND LUNG DISEASE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOSALICYLIC ACID; CAPREOMYCIN; CIPROFLOXACIN; CYCLOSERINE; ETHAMBUTOL; ETHIONAMIDE; KANAMYCIN; OFLOXACIN; PROTIONAMIDE; PYRAZINAMIDE; STREPTOMYCIN;

ADULT; AGED; ANTIBIOTIC RESISTANCE; ARTICLE; COMORBIDITY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IRAN; MAJOR CLINICAL STUDY; MALE; MULTIDRUG RESISTANCE; MYCOBACTERIUM TUBERCULOSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; TUBERCULOSIS;

ADULT; AMIKACIN; ANTI-BACTERIAL AGENTS; CLINICAL PROTOCOLS; CYCLOSERINE; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG THERAPY, COMBINATION; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; FEMALE; HUMANS; IRAN; MALE; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS; OFLOXACIN; PROTHIONAMIDE; TREATMENT OUTCOME; TUBERCULOSIS, PULMONARY;

EID: 77949573574     PISSN: 10766294     EISSN: None     Source Type: Journal    
DOI: 10.1089/mdr.2009.0073     Document Type: Article

References (34)

1. Basu, S., J.R. Andrews, E.M. Poolman, N.R. Gandhi, N.S. Shah, A. Moll, et al. 2007. Prevention of nosocomial transmission of extensively drug-resistant tuberculosis in rural South African district hospitals: an epidemiological modelling study. Lancet 370:1500-1507.
2. Blower, S., and V. Supervie. 2007. Predicting the future of XDR tuberculosis (reflection and reaction). Lancet Infect. Dis. 7:443.
3. Broekmans, J.F., G.B. Migliori, H.L. Rieder, J. Leese, P. Ruutu, R. Loddenkemper, and M.C. Raviglione. 2002. World Health Organization, International Union Against Tuberculosis and Lung Disease, and Royal Netherlands Tuberculosis Association Working Group. European framework for tuberculosis control and elimination in countries with a low incidence. Recommendations of the World Health Organization (WHO), International Union Against Tuberculosis and Lung Disease (IUATLD) and Royal Netherlands Tuberculosis Association (KNCV) Working Group. Eur. Respir. J. 19:765-775.
4. Caminero, J.A. 2005. Management of multidrug-resistant tuberculosis and patients in retreatment. Eur. Respir. J. 25:928-936.
5. Caminero, J.A. 2006. Treatment of multidrug-resistant tuberculosis: evidence and controversies. Int. J. Tuberc. Lung Dis. 10:829-837.
6. Caminero Luna, J.A. 2004. A Tuberculosis Guide for Specialist Physicians. International Union Against Tuberculosis and Lung Disease. Imprimerie Chirat, Paris, pp. 1-411.
7. Centers for Disease Control and Prevention. 2006. Emergence of Mycobacterium tuberculosis with extensive resistance to second-line drugs - worldwide, 2000-2004. Morb. Mortal. Wkly. Rep. 55:301-305.
8. Centers for Disease Control and Prevention. 2007. Extensively drug-resistant tuberculosis - United States, 1993-2006. Morb. Mortal. Wkly. Rep. 56:250-253.
9. Chan, E.D., V. Laurel, M.J. Strand, J.F. Chan, M.L. Huynh, M. Goble, et al. 2004. Treatment and outcome analysis of 205 patients with multidrug-resistant tuberculosis. Am. J. Respir. Crit. Care Med. 169:1103-1109.
10. Chiang, C.Y., D.A. Enarson, M.C. Yu, K.J. Bai, R.M. Huang, C.J. Hsu, et al. 2006. Outcome of pulmonary multidrug- resistant tuberculosis: a 6-yr follow-up study. Eur. Respir. J. 28:980-985.
11. Cox, H.S., S. Kalon, S. Allamuratova, V. Sizaire, Z.N. Tigay, S. Rü sch-Gerdes, et al. 2007. Multidrug-resistant tuberculosis treatment outcomes in Karakalpakstan, Uzbekistan: treatment complexity and XDR-TB among treatment failures. PLoS One 2:e1126.
12. Gandhi, N.R., A. Moll, A.W. Sturm, R. Pawinski, T. Govender, U. Lalloo, et al. 2006. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis in a rural area of South Africa. Lancet 368: 1575-1580.
13. Geerligs, W.A., R. van Altena, W.C.M. de Lange, D. van Soolingen, and T.S. van der Werf. 2005. Multidrug-resistant tuberculosis: long-term treatment outcome in the Netherlands. Int. J. Tuberc. Lung Dis. 4:758-764.
14. Goble, M., M.D. Iseman, L.A. Madsen, D. Waite, L. Ackerson, and C.R. Horsburgh, Jr. 1993. Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampin. N. Engl. J. Med. 328:527-532.
15. Grzybowski, S., and D.A. Enarson. 1978. The fate of cases of pulmonary tuberculosis under various treatment programmes. Bull. Int. Union Tuberc. Lung Dis. 53:70-75.
16. Kent, P.T., and G.P. Kubica. 1985. Public Health Mycobacteriology. A Guide for the Level III Laboratory. U.S. Department of Health and Human Services. Centers for Disease Control, Atlanta, Georgia, pp 1-207.
17. Kim, H.R., S.S. Hwang, H.J. Kim, S.M. Lee, C.G. Yoo, Y.W. Kim, et al. 2007. Impact of extensive drug resistance on treatment outcomes in non-HIV infected patients with multidrug-resistant tuberculosis. Clin. Infect. Dis. 45:1290-1295.
18. Leimane, V., V. Riekstina, T.H. Holtz, E. Zarovska, V. Skripconoka, L.E. Thorpe, et al. 2005. Clinical outcome of individualised treatment of multidrug-resistant tuberculosis in Latvia: a retrospective cohort study. Lancet 365: 318-326.
19. Masjedi, M.R., P. Farnia, S. Sorooch, M.V. Pooramiri, S.D. Mansoori, A.Z. Zarifi, et al. 2006. Extensively drug-resistant tuberculosis: 2 years of surveillance in Iran. Clin. Infect. Dis. 43:841-847.
20. Masjedi, M.R., P. Tabarsi, E. Chitsaz, P. Baghaei, M. Mirsaeidi, M.V. Amiri, et al. 2008. Outcome of treatment of MDR-TB patients with standardized regimens; Iran's experience 2002-2006. Int. J. Tuberc. Lung Dis. 12:750-755.
21. Migliori, G.B., G. Besozzi, E. Girardi, K. Kliiman, C. Lange, O.S. Toungoussova, et al. 2007. Clinical and operational value of the extensively drug-resistant tuberculosis definition. Eur. Respir. J. 30:623-626.
22. Migliori, G.B., C. Lange, R. Centis, G. Sotgiu, R. Mü tterlein, H. Hoffmann, et al. 2008. Resistance to second-line injectables and treatment outcomes in multidrug-resistant and extensively drug-resistant tuberculosis cases. Eur. Respir. J. 31:1155-1159.
23. Migliori, G.B., C. Lange, E. Giardi, R. Centis, G. Besozzi, K. Kliiman, et al. 2008. Extensively drug-resistant tuberculosis is worse than multidrug-resistant tuberculosis: different methodology and settings, same results. Clin. Infect. Dis. 46:958-959.
24. Mirsaedi, M.S., P. Tabarsi, K. Khoshnood, M.V. Pooramiri, A. Rowhani-Rahbar, S.D. Mansoori, et al. 2005. Treatment of multiple drug-resistant tuberculosis (MDR-TB) in Iran. Int. J. Infect. Dis. 9:317-322.
25. Mitnick. C., J. Bayona, E. Palacios, S. Shin, J. Furin, F. Alcántara, et al. 2003. Community-based therapy for multidrug-resistant tuberculosis in Lima, Peru. N. Engl. J. Med. 348:119-128.
26. Narita, M., P. Alonso, M. Lauzardo, E.S. Hollender, A.E. Pitchenik, and D. Ashkin. 2001. Treatment experience of multidrug-resistant tuberculosis in Florida, 1994-1997. Chest 120:343-348.
27. Palmero, D.J., M. Ambroggi, A. Brea, M. De Lucas, A. Fulgenzi, D. Martínez, et al. 2004. Treatment and follow-up of HIV-negative multidrug-resistant tuberculosis patients in an infectious diseases reference hospital, Buenos Aires, Argentina. Int. J. Tuberc. Lung Dis. 8:778-784.
28. Raviglione, M.C., and I.M. Smith. 2007. XDR tuberculosis - implications for global public health. (Perspective). N. Engl. J. Med. 356:656-659.
29. Shah, N.S., A. Wright, G.H. Bai, L. Barrera, F. Boulahbal, N. Mart?́n-Casabona, et al. 2007. Worldwide emergence of extensively drug-resistant tuberculosis. Emerg. Infect. Dis. 13:380-387.
30. Suárez, P.G., K. Floyd, J. Portocarrero, E. Alarcó n, E. Rapiti, G. Ramos, et al. 2002. Feasibility and cost-effectiveness of standardised second-line drug treatment for chronic tuberculosis patients: a national cohort study in Peru. Lancet 359:1980-1989.
31. Van Deun, A., M.A. Hamid Salim, A.P. Kumar Das, I. Bastian, and F. Portaels. 2004. Results of a standardised regimen for multidrug-resistant tuberculosis in Bangladesh. Int. J. Tuberc. Lung Dis. 8:560-567.
32. World Health Organization. 2001. Guidelines for Drug Susceptibility Testing for Second-Line Anti-Tuberculosis Drugs for DOTS-Plus. World Health Organization Document, WHO=CDS=TB=2001. WHO, Geneva, vol.288, pp. 1-12.
33. World Health Organization. 2006. Guidelines of the Programmatic Management of Drug-Resistant Tuberculosis. World Health Organization Document, WHO=HTM=TB=2006. WHO, Geneva, vol.361, pp. 1-174.
34. World Health Organization. 2007. The Global MDR-TB & XDR-TB Response Plan 2007-2008. World Health Organization Document,WHO=HTM=STB=2007.2007. WHO, Geneva, vol.387, pp. 1-51.